• Read more about Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

Although the majority of MDS patients fail to achieve clinical improvement to approved therapies, some patients benefit from treatment. Predicting patient response prior to therapy would improve treatment effectiveness, avoid treatment-related adverse events and reduce healthcare costs. Three separate cohorts of MDS patients were used to simulate drug response to lenalidomide alone, hypomethylating agent (HMA) alone, or HMA plus lenalidomide.

• Read more about Predicting Clinical outcomes in cancer patients based on novel computational biology method of mapping the cancer mutanome

Background: Despite three FDA approved standard of care (SOC) therapeutics, 60% of patients with myelodysplastic syndromes (MDS) fail to achieve hematologic improvement and nearly all patients die of refractory disease.

• Read more about Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome

Background: Unfortunately, 60% of MDS patients fail to achieve a response to HMAs and 33% of del(5q) patients fail to achieve transfusion independence after lenalidomide.